doxercalciferol (hectorol) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease. Doxercalciferol is marketed under the brand name Hectorol by Genzyme Corporation, and is manufactured by Catalent Pharma Solutions, Inc.   NCATS

Chemistry

  • SMILES: CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C3/C[C@@H](O)C[C@H](O)C3=C
  • InChIKey: HKXBNHCUPKIYDM-CGMHZMFXSA-N
  • Mol. Mass: 412.6478
  • ALogP: 6.61
  • ChEMBL Molecule:
    doxercalciferol  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral, Parenteral
  • Pro Drug: Yes

Drug Pricing (per unit)

United States

$0.8444 - $4.9246
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1 alpha-hydroxyergocalciferol | 1-alpha-hydroxyergocalciferol | 1alpha-hydroxyvitamin d2 | 1alpha(oh)2d2 | 1alpha-ohd2 | 1-hydroxyergocalciferol | 1-hydroxyvitamin d2 | (1s,3r,5z,7e,22e)-9,10-secoergosta-5,7,10,22-tetraene-1,3-diol | 1α-hydroxyergocalciferol | doxacalciferol | doxercalciferol | doxercalciferolum | hectorol

Organizations (40)

Research & Development (16)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (25)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (2)


 

Hyperparathyroidism, Secondary (approved 1999)

Renal Insufficiency, Chronic

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 4)

Hyperparathyroidism, Secondary (Phase 4)

Kidney Failure, Chronic (Phase 4)

Kidney Transplantation (Phase 4)

Leukemia (Phase 2)

Myelodysplastic-Myeloproliferative Diseases (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 1)

Parathyroid Hormone (Phase 4)

Prostatic Neoplasms (Phase 2)

Psoriasis (Phase 2)

Renal Insufficiency (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Vascular Calcification (Phase 4)

Vitamin D Deficiency (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 20
  • # of Trial Organizations: 16

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue